Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?

Lung Cancer

Volumn 64, Issue 2, 2009, Pages 207-210

  Li, Louise ^a   Razak, Albiruni Ryan Abdul ^a   Hughes, Andrew ^a  

^a Northern Centre for Cancer Treatment   (United Kingdom)

Author keywords

Carboplatin; Chemotherapy; Disease control; Mesothelioma; Pemetrexed; Pleural; Retrospective; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PEMETREXED; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION COMPLICATION; MALE; MALIGNANT PLEURAL MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 63049089229     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.08.016     Document Type: Article

References (12)

1. Bianchi C., Giarelli L., Grandi G., Brollo A., Ramani L., and Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 6 2 (1997) 162-166
2. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., and Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92 3 (2005) 587-593
3. Peto J., Hodgson J.T., Matthews F.E., and Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet 345 8949 (1995) 535-539
4. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klavaren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 28 (2005) 6881-6889
5. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
6. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 16 (2002) 3533-3544
7. Castagneto B., Botta M., Aitini E., Spigno F., Degiovanni D., Alabiso O., et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19 2 (2008) 370-373
8. Ceresoli G.L., Zucali P.A., Favaretto A.G., Grossi F., Bidoli P., Del Conte G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 9 (2006) 1443-1448
9. Hazarika M., White Jr. R.M., Booth B.P., Wang Y.C., Ham P.Y., Liang C.Y., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 3 (2005) 982-992
10. Niyikiza C., Hanauske A.R., Rusthoven J.J., Calvert A.H., Allen R., Paoletti P., et al. Pemetrexed safety and dosing strategy. Semin Oncol 29 6 Suppl. 18 (2002) 24-29
11. Hennessy B.T., Gauthier A.M., Michaud L.B., Hortobagyi G., and Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16 8 (2005) 1289-1296
12. Fennell D., Steele J., and Sheaff M. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49. Suppl. 2 (2005)